Last reviewed · How we verify
ferumoxytol or oral iron
ferumoxytol or oral iron is a Iron replacement therapy Small molecule drug developed by AMAG Pharmaceuticals, Inc.. It is currently in Phase 3 development for Treatment of iron deficiency anemia in adult patients with chronic kidney disease.
Ferumoxytol is an intravenous iron replacement therapy that works by replenishing iron stores in the body.
Ferumoxytol is an intravenous iron replacement therapy that works by replenishing iron stores in the body. Used for Treatment of iron deficiency anemia in adult patients with chronic kidney disease.
At a glance
| Generic name | ferumoxytol or oral iron |
|---|---|
| Sponsor | AMAG Pharmaceuticals, Inc. |
| Drug class | Iron replacement therapy |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
It does this by being taken up by macrophages in the reticuloendothelial system, where it is stored and gradually released into the bloodstream, thereby increasing the body's iron levels. This helps to alleviate anemia in patients with iron deficiency. Ferumoxytol is a superparamagnetic iron oxide nanoparticle.
Approved indications
- Treatment of iron deficiency anemia in adult patients with chronic kidney disease
Common side effects
- Nausea
- Headache
- Diarrhea
- Fatigue
- Dizziness
Key clinical trials
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Sucrosomial Vs Intravenous Iron for Preoperative Anemia (PHASE4)
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma (PHASE1)
- Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia (NA)
- Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient (PHASE3)
- Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients (PHASE3)
- Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients (PHASE3)
- Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ferumoxytol or oral iron CI brief — competitive landscape report
- ferumoxytol or oral iron updates RSS · CI watch RSS
- AMAG Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about ferumoxytol or oral iron
What is ferumoxytol or oral iron?
How does ferumoxytol or oral iron work?
What is ferumoxytol or oral iron used for?
Who makes ferumoxytol or oral iron?
What drug class is ferumoxytol or oral iron in?
What development phase is ferumoxytol or oral iron in?
What are the side effects of ferumoxytol or oral iron?
Related
- Drug class: All Iron replacement therapy drugs
- Manufacturer: AMAG Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Treatment of iron deficiency anemia in adult patients with chronic kidney disease
- Compare: ferumoxytol or oral iron vs similar drugs
- Pricing: ferumoxytol or oral iron cost, discount & access